Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-442-4 | CAS number: 106-92-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Short description of key information on bioaccumulation potential result:
After i.p. injection allyl glycidyl ether (AGE) was partly metabolised by epoxidation or hydrolysis to diglycidyl ether, 1-allyloxy-2,3-dihydroxypropane and/or 2,3-dihydroxypropyl glycidyl ether.
Short description of key information on absorption rate:
Allyl Glycidyl Ether (AGE), without metabolic activation, directly react with N-terminal valine (AGEVal).
Key value for chemical safety assessment
Additional information
Metabolism of the double bond of AGE leading to formation of the reactive epoxides I and III was investigated in mice administered by i.p. injection or by skin application (Perez 2000). Hemoglobin adducts were determined using the modified Edman method with gas chromatography: tandem mass spectrometry (GC/MS-MS) for adduct detection. Adducts of I or III with N-terminal valine, diOHPrGEVal, were demonstrated in mice administered AGE by i.p. injection, which were one to five times higher than those of AGEVal previously found in mice after identical treatment with the compound. The levels of AGEVal in the mice treated with AGE by skin application varied between individual animals and were considerably lower than those found in mice treated by i.p. injection. diOHPrGEVal was not detected in animals treated by skin application (detection limit 20 pmol/g globin) and, therefore, the levels were probably lower than those of AGEVal. These observations may be explained by different disposition of AGE following i.p. injection or skin application. Probably formation of I and III mainly occurs in the liver. A more extensive formation of I and III following i.p. injection of AGE is in accordance with a first path effect in the liver. After penetration through the skin, a larger fraction of the compound is systemically distributed.
Discussion on bioaccumulation potential result:
In a metabolism study (Pérez HL and Osterman-Golkar S, 2000), male mice (n=9) were administered a single intraperitoneal injection (i.p.) of 4 mg/mouse AGE diluted in tricaprylin. Adducts to N-terminal valine in haemoglobin were analysed. The adduct N-(2-hydroxy-3-(2,3-dihydroxy)propyloxy)propylvaline (diOHPrGEVal) was demonstrated to be present at 1600-5600 pmol/g globin in mice. This adduct can be formed after P450-catalysed epoxidation or epoxide hydrolase-catalysed hydrolysis of AGE. Also adduct formation from allyl glycidyl ether directly with N-terminal valine (AGEVal) was found at 1600 pmol/g globin. The study shows that after i.p. injection allyl glycidyl ether was partly metabolised by epoxidation and/or hydrolysis to diglycidyl ether, 1-allyloxy-2,3-dihydroxypropane and/or 2,3-dihydroxypropyl glycidyl ether.
In another study (Pérez et al., 1997), groups of 3 mice each were administered with AGE, 0, 2 and 4 mg/mouse, by i.p. injection diluted in tricaprylin. The animals were sacrificed 24 h after injection and blood was collected in heparinised tubes. Four mice were administered AGE (4 mg/mouse) at the same conditions as the other mice and blood was collected after 21 days. Hemoglobin adducts were assessed in the blood samples using the N-alkyl Edman method. A linear relation between administered amount of the chemical and adduct formation in the dose range studied (0, 2 and 4 mg/mouse) was observed. The adduct levels were similar 24 h and 21 days after exposure. The result indicates that adducts are chemically stable and that the exposure had no influence on the turnover of erythrocytes (the life span of erythrocytes in the mouse is about 40 days) or a stability of the hemoglobin molecule itself. In the same study, erythrocytes isolated from mouse, or human whole blood were treated with AGE at 37° C in-vitro, and the adduct levels were determined. It was found that the rate constants for the reaction of AGE with N-terminal valine residues in haemoglobin were similar in mouse and human erythrocytes.
Discussion on absorption rate:
In the same metabolism study as discussed above in chapter 7.1.1 (Pérez HL and Osterman-Golkar S, 2000), male mice (n=11) were administered 4 mg/mouse of AGE dissolved in acetone, by skin application. Adducts to N-terminal valine in haemoglobin were analysed. The level of AGEVal (AGE reacted with N-terminal valine) was about 20 pmol/g globin. The other adducts were below the detection limit.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.